-

Shareholder Alert: Did You Purchase Shares of Arqit Quantum Inc. (ARQQ) f/k/a Centricus Acquisition Corp. (CENH)? Robbins LLP Alerts Investors of Class Action Against Arqit Quantum Inc.

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Arqit Quantum Inc. (NASDAQ: ARQQ) securities (i) between September 7, 2021 and April 18, 2022 and/or (ii) all holders of Centricus securities as of the record date for the special meeting of shareholders held on August 31, 2021, to consider approval of the merger between Arqit and Centricus. The complaint alleges violations of the Securities Exchange Act of 1934. Arqit claims to be a cybersecurity company that has pioneered a unique quantum encryption technology.

If you would like more information about Arqit Quantum Inc.'s misconduct, click here.

What is this Case About: Arqit Quantum Inc. (ARQQ) Made Misleading Statements in its Offering Documents in Support of its Merger with Centricus Acquisition Corp. (CENH)

According to the complaint, in connection with the merger with Centricus, Arqit alleged its quantum encryption technology would be secure against current and future forms of cyberattacks, including from a quantum computer. Arqit also represented that it had "already signed major, long-term contracts for its services with large companies and government institutions."

However, defendants failed to disclose that Arqit’s proposed encryption technology would require widespread adoption of new protocols and standards for telecommunications, with British cybersecurity officials having questioned the viability of Arqit’s proposed encryption technology in a meeting in 2020. Further, the British government was not an Arqit customer but, rather, providing grants to Arqit, and Arqit had little more than an early-stage prototype of its encryption system at the time of the merger.

These facts became known on April 18, 2022, when The Wall Street Journal published an article titled, "British Encryption Startup Arqit Overstates Its Prospects, Former Staff and Others Say." On this news, Arqit share price fell $2.57 per share, or 17%, to close at $12.4 per share on April 18, 2022.

Next Steps: If you acquired shares of Arqit Quantum Inc. (ARQQ) f/k/a Centricus Acquisition Corp. between September 7, 2021 and April 18, 2022, or held Centricus securities and were entitled to vote on the merger, you have until July 5, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Arqit Quantum Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:ARQQ

Release Summary
Arqit Quantum Inc. (ARQQ) Made Misleading Statements in its Offering Documents in Support of its Merger with Centricus Acquisition Corp. (CENH)
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom